Gala­pa­gos CSO hits the ex­it as the biotech looks to pick up the pieces af­ter FDA's fil­go­tinib re­jec­tion

Months af­ter Gala­pa­gos cut away broad swaths of its pipeline fol­low­ing a re­jec­tion for Gilead-part­nered rheuma­toid arthri­tis drug fil­go­tinib, the biotech will now say good­bye …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER